Assessment of rituximab’s immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results

OBJECTIVE: Treatment with the anti-CD20 monoclonal antibody (mAb) rituximab is effective in rheumatoid arthritis (RA). Marked depletion of circulating B cells, seen in almost all patients, does not correlate with efficacy. The potential synovial immunomodulatory effects of rituximab have not been fu...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Kavanaugh, A, Rosengren, S, Lee, S J, Hammaker, D, Firestein, G S, Kalunian, K, Wei, N, Boyle, D L
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2007
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2754142/
https://ncbi.nlm.nih.gov/pubmed/17644541
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ard.2007.074229
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller